rezatomidine
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00381719)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Histamine H2 receptorINHIBITOR
HRH2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cccc([C@H](C)c2c[nH]c(=S)[nH]2)c1C- Mol. weight
- 232.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107366 ↗
Also known as
- agn 203818
- agn 203818
- rezatomidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00441766 | Phase 2 | Mar 1, 2007 | Allergan |
| NCT00445705 | Phase 2 | Mar 1, 2007 | Allergan |
| NCT00380783 | Phase 2 | Oct 1, 2006 | Allergan |
| NCT00381719 | Phase 2 | Oct 1, 2006 | Allergan |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 4 | 4 | 1 | 2006 |
1 organizations
Page 1 / 1